Promoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian Cancer.
OBJECTIVE
To assess the 5' CpG island methylation of Fanconi anemia, complementation group F (FANCF) gene in epithelial ovarian cancer (EOC) tissues and normal ovarian tissues and to investigate the relationship between FANCF methylation and clinicopathologic features and prognosis of EOC.


METHODS
The experiment was performed with 112 EOC tissue samples (case group) and 60 normal ovarian tissues (control group). With methylation-specific polymerase chain reaction (MSP), FANCF methylation status of cases and controls was assessed. And the association between FANCF methylation and the clinicopathological features of EOC was investigated with univariate survival analysis and Cox regression model analysis.


RESULTS
The methylation-positive rate of the case group was significantly higher than that of the control group (P = 0.015). The FANCF promoter methylation rates showed significant differences in the comparisons stratified by age, International Federation of Gynecology and Obstetrics (FIGO) staging, histopathological classification, and lymph node metastasis (all P < .05). Univariate survival analysis showed there were significant differences in mean survival time between the groups based on FIGO staging, histopathological classification, lymph node metastasis, and FANCF methylation (all P < .05). Cox regression model analysis suggested that FIGO staging and FANCF methylation were independent risk factors for EOC prognosis.


CONCLUSIONS
CpG island methylation of FANCF gene promoter region is strongly associated with the susceptibility and clinicopathologic features of EOC. The FIGO staging and FANCF methylation are independent risk factors for EOC prognosis.
Department of Obstetrics and Gynecology, Chinese PLA General Hospital, Beijing, China.
Jia-Jia
JJ
Ding
Department of Gynecology, Tianjin central Hospital of Obstetrics and Gynecology, Tianjin, China.
Guan
G
Wang
Department of Obstetrics and Gynecology, Chinese PLA General Hospital, Beijing, China.
Wen-Xin
WX
Shi
Department of Obstetrics and Gynecology, Chinese PLA General Hospital, Beijing, China.
Hong-Hui
HH
Zhou
Department of Obstetrics and Gynecology, Chinese PLA General Hospital, Beijing, China zhaoenfeng830_ooo@126.com.
En-Feng
EF
Zhao
D000367:Age Factors; D000077216:Carcinoma, Ovarian Epithelial; D016022:Case-Control Studies; D018899:CpG Islands; D019175:DNA Methylation; D052219:Fanconi Anemia Complementation Group F Protein / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D020022:Genetic Predisposition to Disease; D006801:Humans; D008207:Lymphatic Metastasis / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D011401:Promoter Regions, Genetic; D015996:Survival Rate
D052219:Fanconi Anemia Complementation Group F Protein
FANCF; MSP; clinicopathologic features; epithelial ovarian cancer; methylation; prognosis; survival analysis; treatment